New Insights in the Treatment of DKD: Recent Advances and Future Prospects

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2025 Feb 11

PMID 39934650

Authors

Meimei Zhao

Yongtong Cao

Liang Ma

Affiliations

Soon will be listed here.

Abstract

Diabetic kidney disease (DKD) represents the predominant and severe microvascular complication associated with diabetes, frequently culminating in End-Stage Kidney Disease (ESKD). The escalating prevalence of diabetes has correspondingly led to a rise in DKD incidence, imposing significant challenges on both individuals and society. The etiology of DKD is multifaceted and remains devoid of definitive therapeutic interventions. This article examines the pharmacological actions and mechanisms of different drugs used for the prevention and treatment of DKD that are currently in clinical use or undergoing development. The goal is to offer insights for early intervention based on therapeutic combinations to potentially slow kidney disease progression.

References

Nauck M, Quast D, Wefers J, Meier J . GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2020; 46:101102. PMC: 8085572. DOI: 10.1016/j.molmet.2020.101102. View

Tang H, Zhang P, Zeng L, Zhao Y, Xie L, Chen B . Mesenchymal stem cells ameliorate renal fibrosis by galectin-3/Akt/GSK3β/Snail signaling pathway in adenine-induced nephropathy rat. Stem Cell Res Ther. 2021; 12(1):409. PMC: 8283866. DOI: 10.1186/s13287-021-02429-z. View

Khalid M, Petroianu G, Adem A . Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules. 2022; 12(4). PMC: 9030615. DOI: 10.3390/biom12040542. View

Packham D, Fraser I, Kerr P, Segal K . Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study. EBioMedicine. 2016; 12:263-269. PMC: 5078602. DOI: 10.1016/j.ebiom.2016.09.011. View

Lindsay S, Moleda A, MacLellan L, Keh S, McElroy D, Linington C . Human olfactory mesenchymal stromal cell transplantation ameliorates experimental autoimmune encephalomyelitis revealing an inhibitory role for IL16 on myelination. Acta Neuropathol Commun. 2022; 10(1):12. PMC: 8800340. DOI: 10.1186/s40478-022-01316-9. View

Scholtes R, Hesp A, Mosterd C, Geurts F, Hoorn E, Touw D . Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes. Circulation. 2022; 146(24):1895-1897. DOI: 10.1161/CIRCULATIONAHA.122.061033. View

Smits M, van Raalte D . Safety of Semaglutide. Front Endocrinol (Lausanne). 2021; 12:645563. PMC: 8294388. DOI: 10.3389/fendo.2021.645563. View

Tuttle K, Brosius 3rd F, Adler S, Kretzler M, Mehta R, Tumlin J . JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrol Dial Transplant. 2018; 33(11):1950-1959. PMC: 6212720. DOI: 10.1093/ndt/gfx377. View

Zhang S, Cai Y, Meng C, Ding X, Huang J, Luo X . The role of the microbiome in diabetes mellitus. Diabetes Res Clin Pract. 2020; 172:108645. DOI: 10.1016/j.diabres.2020.108645. View

10.

Chen P, Zhang J, Li X, Li L, Wu Q, Liu L . Outer membrane vesicles derived from gut microbiota mediate tubulointerstitial inflammation: a potential new mechanism for diabetic kidney disease. Theranostics. 2023; 13(12):3988-4003. PMC: 10405836. DOI: 10.7150/thno.84650. View

11.

Wei H, Ren J, Li R, Qi X, Yang F, Li Q . Global, regional, and national burden of chronic kidney disease attributable to high fasting plasma glucose from 1990 to 2019: a systematic analysis from the global burden of disease study 2019. Front Endocrinol (Lausanne). 2024; 15:1379634. PMC: 11004380. DOI: 10.3389/fendo.2024.1379634. View

12.

Frampton J . Finerenone: First Approval. Drugs. 2021; 81(15):1787-1794. DOI: 10.1007/s40265-021-01599-7. View

13.

Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan R, Antunes M . 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39):4043-4140. DOI: 10.1093/eurheartj/ehad192. View

14.

Agarwal R, Filippatos G, Pitt B, Anker S, Rossing P, Joseph A . Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022; 43(6):474-484. PMC: 8830527. DOI: 10.1093/eurheartj/ehab777. View

15.

Wu Q, Huang F . LncRNA H19: a novel player in the regulation of diabetic kidney disease. Front Endocrinol (Lausanne). 2023; 14:1238981. PMC: 10641825. DOI: 10.3389/fendo.2023.1238981. View

16.

Wang S, Zhou Y, Zhang Y, He X, Zhao X, Zhao H . Roscovitine attenuates renal interstitial fibrosis in diabetic mice through the TGF-β1/p38 MAPK pathway. Biomed Pharmacother. 2019; 115:108895. DOI: 10.1016/j.biopha.2019.108895. View

17.

Salem R, Todd J, Sandholm N, Cole J, Chen W, Andrews D . Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. J Am Soc Nephrol. 2019; 30(10):2000-2016. PMC: 6779358. DOI: 10.1681/ASN.2019030218. View

18.

Rayego-Mateos S, Rodrigues-Diez R, Fernandez-Fernandez B, Mora-Fernandez C, Marchant V, Donate-Correa J . Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2022; 103(2):282-296. DOI: 10.1016/j.kint.2022.10.030. View

19.

van Raalte D, Bjornstad P, Cherney D, de Boer I, Fioretto P, Gordin D . Combination therapy for kidney disease in people with diabetes mellitus. Nat Rev Nephrol. 2024; 20(7):433-446. DOI: 10.1038/s41581-024-00827-z. View

20.

Yao L, Liang X, Qiao Y, Chen B, Wang P, Liu Z . Mitochondrial dysfunction in diabetic tubulopathy. Metabolism. 2022; 131:155195. DOI: 10.1016/j.metabol.2022.155195. View